Accession | ARO:3007147 |
Synonym(s) | VNRX-5133 |
Definition | Taniborbactam is a broad-spectrum beta-lactamase inhibitor. As of 2022, it is in phase III clinical trials in combination with cefepime and is the only beta-lactamase inhibitor exhibiting activity against all four classes of beta-lactamase. |
Classification | 6 ontology terms | Show |
Parent Term(s) | 11 ontology terms | Show + is_small_molecule_inhibitor NDM-2 + is_small_molecule_inhibitor SHV-5 + is_small_molecule_inhibitor OXA-1 + is_small_molecule_inhibitor OXA-48 + is_small_molecule_inhibitor CTX-M-15 + is_small_molecule_inhibitor CMY-2 + is_small_molecule_inhibitor IMP-1 + is_small_molecule_inhibitor VIM-2 + is_small_molecule_inhibitor KPC-2 + boronic acid beta-lactamase inhibitor + unclassified metallo-beta-lactamase inhibitor |
Sub-Term(s) | 1 ontology terms | Show + cefepime-taniborbactam [Antibiotic+Adjuvant] has_part |
Publications | Hamrick JC, et al. 2020. Antimicrob Agents Chemother 64(3): VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa. (PMID 31871094) |